Taro admits collusion to end DOJ probe
Taro Pharmaceuticals has entered into a deferred prosecution agreement with the Antitrust Division, but it is costing the generic drugmaker $419 million and an admission that its price-fixing conspiracy impacted more than $500 million worth of commerce.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10